Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6.1% – Here’s Why

Capricor Therapeutics Inc (NASDAQ:CAPR) was down 6.1% on Wednesday . The stock traded as low as $13.95 and last traded at $14.16. Approximately 571,359 shares were traded during trading, a decline of 26% from the average daily volume of 774,542 shares. The stock had previously closed at $15.07.

Analyst Upgrades and Downgrades

CAPR has been the subject of a number of research analyst reports. Cantor Fitzgerald upped their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Thursday, January 2nd. Finally, Piper Sandler started coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price target on the stock. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Trading Down 1.7 %

The business’s fifty day moving average price is $14.34 and its 200 day moving average price is $12.46. The firm has a market capitalization of $640.67 million, a price-to-earnings ratio of -13.29 and a beta of 4.08.

Institutional Trading of Capricor Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Black Diamond Financial LLC acquired a new position in Capricor Therapeutics during the 4th quarter worth approximately $3,833,000. Point72 Asset Management L.P. acquired a new position in shares of Capricor Therapeutics during the 3rd quarter worth $3,806,000. PFM Health Sciences LP purchased a new position in shares of Capricor Therapeutics in the 3rd quarter valued at about $2,324,000. State Street Corp lifted its stake in shares of Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after purchasing an additional 111,291 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Capricor Therapeutics during the second quarter worth about $426,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.